IL214545A - Use of a human prolactin receptor antagonist in the preparation of cancer growth inhibition drug - Google Patents

Use of a human prolactin receptor antagonist in the preparation of cancer growth inhibition drug

Info

Publication number
IL214545A
IL214545A IL214545A IL21454511A IL214545A IL 214545 A IL214545 A IL 214545A IL 214545 A IL214545 A IL 214545A IL 21454511 A IL21454511 A IL 21454511A IL 214545 A IL214545 A IL 214545A
Authority
IL
Israel
Prior art keywords
medicament
preparation
cancer cells
receptor antagonist
inhibiting growth
Prior art date
Application number
IL214545A
Other languages
English (en)
Hebrew (he)
Other versions
IL214545A0 (en
Original Assignee
Oncolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolix Inc filed Critical Oncolix Inc
Publication of IL214545A0 publication Critical patent/IL214545A0/en
Publication of IL214545A publication Critical patent/IL214545A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5756—Prolactin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL214545A 2009-02-26 2011-08-09 Use of a human prolactin receptor antagonist in the preparation of cancer growth inhibition drug IL214545A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15562409P 2009-02-26 2009-02-26
PCT/US2010/024340 WO2010099003A2 (en) 2009-02-26 2010-02-16 Compositions and methods for visualizing and eliminating cancer stem cells

Publications (2)

Publication Number Publication Date
IL214545A0 IL214545A0 (en) 2011-09-27
IL214545A true IL214545A (en) 2016-07-31

Family

ID=42133705

Family Applications (2)

Application Number Title Priority Date Filing Date
IL214545A IL214545A (en) 2009-02-26 2011-08-09 Use of a human prolactin receptor antagonist in the preparation of cancer growth inhibition drug
IL246247A IL246247A0 (en) 2009-02-26 2016-06-15 Use of an anti-human prolactin receptor in the preparation of a drug to inhibit the growth of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL246247A IL246247A0 (en) 2009-02-26 2016-06-15 Use of an anti-human prolactin receptor in the preparation of a drug to inhibit the growth of cancer

Country Status (9)

Country Link
US (1) US8754035B2 (enExample)
EP (1) EP2400979B1 (enExample)
JP (2) JP5963443B2 (enExample)
KR (1) KR101672401B1 (enExample)
CN (2) CN106177954A (enExample)
AU (1) AU2010218261B2 (enExample)
CA (1) CA2753804C (enExample)
IL (2) IL214545A (enExample)
WO (1) WO2010099003A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2576823A1 (en) * 2010-06-04 2013-04-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
TW201920283A (zh) 2012-12-24 2019-06-01 美商艾伯維有限公司 催乳激素受體結合蛋白質及其用途
WO2015193417A1 (en) * 2014-06-18 2015-12-23 Prorec Bio Ab Prolactin receptor antagonists for treatment of glioblastoma
CN107198779A (zh) * 2016-11-29 2017-09-26 南京东纳生物科技有限公司 一种干细胞标记示踪及靶向导航的纳米偶联复合物及其制备方法和应用
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
WO2020011998A1 (en) * 2018-07-13 2020-01-16 Hifibio Sas Use of droplet single cell epigenome profiling for patient stratification
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
ATE366114T1 (de) * 1998-05-12 2007-07-15 Greenville Hospital System Verwendung von anti-prolaktin agentien zur behandlung von krebs
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001085777A2 (en) 2000-05-09 2001-11-15 Greenville Hospital System Therapeutic pore-forming peptides
KR100567718B1 (ko) * 2001-07-31 2006-04-05 화이자 프로덕츠 인크. 에스트로겐 작용제/길항제와 에스트로겐과 프로게스틴의조합을 포함하는 약학 조성물, 키트 및 방법
AU2003230750A1 (en) 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
RU2329274C2 (ru) 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
MXPA05006945A (es) 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US20050238628A1 (en) 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
US8420665B2 (en) 2008-01-11 2013-04-16 Northwestern University Anti-cancer compounds

Also Published As

Publication number Publication date
JP2014156484A (ja) 2014-08-28
EP2400979A2 (en) 2012-01-04
CA2753804A1 (en) 2010-09-02
CA2753804C (en) 2018-03-13
AU2010218261B2 (en) 2015-08-20
WO2010099003A2 (en) 2010-09-02
AU2010218261A1 (en) 2011-09-01
US20100215577A1 (en) 2010-08-26
CN106177954A (zh) 2016-12-07
KR101672401B1 (ko) 2016-11-16
WO2010099003A3 (en) 2011-02-17
KR20110139703A (ko) 2011-12-29
IL214545A0 (en) 2011-09-27
JP5963443B2 (ja) 2016-08-03
US8754035B2 (en) 2014-06-17
JP2012519168A (ja) 2012-08-23
EP2400979B1 (en) 2015-05-20
CN102341118A (zh) 2012-02-01
IL246247A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
IL246247A0 (en) Use of an anti-human prolactin receptor in the preparation of a drug to inhibit the growth of cancer
IL211312A (en) Use of negative isolate cells for drug preparation
ZA201204214B (en) Neutralizing prolactin receptor antibodies and their therapeutic use
IL253648B (en) The device intended for implantation in a patient's heart
EP2499147A4 (en) IMPROVED METHODS FOR THE PRODUCTION OF PRASUGREL AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
IL223253B (en) History of 2-(piperidin-2-yl)-pyrazolo[1,5-a]pyrimidine and their use in the preparation of drugs against pneumovirina
IL233822A (en) Use of a compound to prepare a drug to inhibit the expression of 6-il and / or 1-vcam
IL211279A (en) Use of the tspan12 antagonist in the preparation of a blood vessel inhibition drug
IL216226A0 (en) Cyclopenta [c] pyrrole-2-carboxylate derivatives, preparation thereof, and therapeutic use thereof
IL213502A (en) Use of agonist d1 / d2 compounds for drug preparation
IL215690A0 (en) Thiazole derivatives and their use as p2y12 receptor antagonists
PL3095441T3 (pl) Szybko rozpuszczająca się w jamie ustnej postać dawkowania szczepionki z wykorzystaniem skrobi
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
IL214260A0 (en) Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof
SI2379066T1 (sl) Uporaba opioidnih antagonistov za pripravo zdravila za zdravljenje degenerativnih bolezni retine
IL218230B (en) Use of lapatinib or an acceptable pharmaceutical salt or preparation thereof for the preparation of a drug for the treatment of cancer
SI2421864T1 (sl) 1-pirazolo(4,3-c)izokinolinski derivati, njihova priprava in njihova terapevtska uporaba
IL214544A0 (en) Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof
EP2386301A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLOPIDINE OR PHARMACEUTICAL ACCEPTABLE SALTS AND BETA BLOCKERS, AND USE THEREOF
PL2477990T3 (pl) Pochodne 5-fenylopirazolopirydyny, ich wytwarzanie oraz ich zastosowanie terapeutyczne
PL2513099T3 (pl) Wytwarzanie związków n-monofluoroalkilowych
EP2474294A4 (en) PREPARATION FOR ORAL ADMINISTRATION
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
IL226388A0 (en) New indolizine derivatives, their preparation and medical use
EP2480188A4 (en) IMPLANTABLE WUNDAUFLAGE AND SURGICAL KIT FOR THEIR PRODUCTION

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees